Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide.

Trial Profile

Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Feb 2015

At a glance

  • Drugs Busulfan (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Graft-versus-host disease; Hodgkin's disease; Multiple myeloma; Myeloproliferative disorders; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jan 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 30 Jan 2012 Actual patient number is 95 according to ClinicalTrials.gov.
    • 30 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top